Tag: Tetracyclic norepinephrine reuptake inhibitor

  • Maprotiline

    Tetracyclic norepinephrine reuptake inhibitor

    A tetracyclic NRI with TCA-like side effects but selective noradrenergic action; significant seizure risk at high dose.

    Abstract

    Maprotiline (N-methyl-9,10-ethanoanthracene-9(10H)-propylamine; CAS 10262-69-8; molecular formula C20H23N; molecular weight 277.40) is a tetracyclic norepinephrine reuptake inhibitor developed at Ciba-Geigy and approved in the US in 1980 under the trade name Ludiomil. NET affinity is approximately 11 nM with very weak SERT activity (Ki greater than 1 microM), making the compound a selective NRI structurally classed with the tetracyclics owing to its bridged anthracene scaffold. Significant H1 (Ki approximately 2 nM) and muscarinic activity produces a side effect profile resembling tricyclic antidepressants: sedation, anticholinergic effects, weight gain. Plasma half-life is 21 to 52 hours, the longest of the antidepressant class, owing to the bridged scaffold’s resistance to CYP metabolism. The seizure risk and TCA-like adverse profile have led to declining use in favor of mirtazapine and SSRIs.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.